LivaNova Grabs CE Mark for Vagus Nerve Stimulation Therapy

LivaNova has earned the CE Mark for its Symmetry vagus nerve stimulation (VNS) therapy for difficult-to-treat depression.

Symmetry is a small implantable device that improves depression symptoms by stimulating the cranial nerve linked to parts of the brain that control mood.

The device received the FDA’s approval in September 2019. It is indicated in the U.S. for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.